The official language of the symposium is English. Simultaneous translation into Spanish will be provided.

ACCREDITATION
Accreditation requested to the Spanish Authorities of Continuing Medical Education.

LANGUAGE

VENUE
Palau de la Música
“Iturbi” Meeting Room
Paseo de la Alameda, 30 · 46023 Valencia, Spain

SYMPOSIUM SECRETARIAT
E-mail: aocsymp2019@doctaforum.com
Phone: +34 913 72 02 03
Web: www.valencia-ovariancancersymp.org

SCIENTIFIC COMMITTEE
Andrés Cervantes (ESMO,GEICO)
Antonio González (ESMO,GEICO)
Andrés Poveda (ESMO,GEICO)
Jan B. Vermorken (ESMO,GEICO)

AOC 12th 2019

ACCREDITATION

ORGANIZED BY

Valencia, 22nd February 2019

12th International Symposium
ADVANCED OPTIMAL THERAPY. UPDATE

OVARIAN CANCER

Andrés Poveda
Initia Oncology, Hospital Quirónsalud, Valencia, Spain

Jan B. Vermorken
Antwerp University Hospital, Belgium

SCIENTIFIC COMMITTEE

www.valencia-ovariancancersymp.org
VENUE
Palau de la Música
"Iturbi" Meeting Room
Paseo de la Alameda, 30 · 46023 Valencia, Spain

SYMPOSIUM SECRETARIAT
E-mail: aocsymp2019@doctaforum.com
Phone: +34 913 72 02 03
Web: www.valencia-ovariancancersymp.org

12th International Symposium
ADVANCED OPTIMAL THERAPY. UPDATE
Valencia, 22nd February 2019

Andrés Poveda
Initia Oncology, Hospital Quirónsalud, Valencia, Spain
Jan B. Vermorken
Antwerp University Hospital, Edegem, Belgium

DIRECTORS

www.valencia-ovariancancersymp.org

LANGUAGE
The official language of the symposium is English. Simultaneous translation into Spanish will be provided.

ACCREDITATION
Accreditation requested to the Spanish Authorities of Continuing Medical Education

SCIENTIFIC COMMITTEE
Andrés Cervantes (ESMO, GEICO)
Antonio González (ESMO, GEICO)
Andrés Poveda (ESMO, GEICO)
Jan B. Vermorken (ESMO, GEICO)

www.valencia-ovariancancersymp.org
Valencia, 22nd February 2019

12th International Symposium ADVANCED OPTIMAL THERAPY. UPDATE

**KEYNOTE LECTURE**
Chairs: Antonio González, Fundación Instituto Valenciano de Oncología, Valencia, Spain
Andrés Poveda, Initia Oncology, Hospital Quirónsalud, Valencia, Spain

8:00-8:30

Biomarkers in Ovarian Cancer: To be or not to be
Michael Birrer, Massachusetts General Hospital, Boston (MA), USA

SESSION 1: TRANSLATIONAL RESEARCH
Chairs: Michael Birrer, Massachusetts General Hospital, Boston (MA), USA
Jose A. López-Guerrero, Fundación Instituto Valenciano de Oncología, Valencia, Spain

8:35-8:55

Precision medicine in epithelial ovarian cancer
Iain McNeish, Imperial College London, UK

8:55-9:15

The potential role of liquid biopsies in ovarian cancer
Martin Willemse, University Medical Center Utrecht, Utrecht, the Netherlands

9:15-9:35

The TILs and PD-L1 expression in ovarian cancer: What to do with it?
George Gudjonsson, University of Lausanne, Switzerland

9:35-9:55

Discussion

10:00-10:30

Coffee Break

SESSION 2: TREATMENT OF PRIMARY DISEASE
Chairs: Jonathan A. Ledermann, UCL Cancer Institute, University College, London, UK
Luis Chiva, Clínica Universidad de Navarra, Madrid, Spain

10:35-10:55

How to manage lymph nodes in ovarian cancer in 2019
Philipp Harter, Kliniken Essen-Mitte, Essen, Germany

10:55-11:15

Can we predict who lives long with ovarian cancer?
Michael A. Bookman, Kaiser Permanente Northern California, (CA), USA

11:15-11:35

Landscape of systemic therapy for ovarian cancer in 2019
Keiichi Fujiwara, Saitama Medical University, Saitama, Japan

11:35-11:55

Discussion

12:00-12:30

Does HIPEC improve survival in AOC?
Chairs: Jan B. Vermorken, Antwerp University Hospital, Edegem, Belgium
Giovanni Scambia, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy

**PRO:**
Gabe Sonke, Netherlands Cancer Institute, Amsterdam, The Netherlands

**CONS:**
Ignace Vergote, UZ Leuven, Belgium

12:30-12:50

Discussion

13:00-13:30

Lunch

SESSION 3: TREATMENT OF RECURRENT DISEASE
Chairs: Eric Pujade-Lauraine, Hôpital Hotel-Dieu, Paris, France
Ana Oaknin, Vall d`Hebron University Hospital. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

13:35-13:55

Who needs surgery?
Jalid Sehouli, Charité University of Medicine, Berlin, Germany

13:55-14:15

Do all patients need systemic therapy?
Michael Friedlander, The Prince of Wales Hospital, Randwick, Australia

14:15-14:35

Landscape of systemic therapy for recurrent ovarian cancer in 2019
Sandro Pignata, NIRCCS National Cancer Institute “Fondazione G. Pascale”, Napoli, Italy

14:35-14:55

Discussion

15:00-15:30

Immunotherapy in Ovarian Cancer: Still promising?
Antonio González, Clínica Universidad de Navarra, Madrid, Spain

15:30-15:50

New Strategies in Ovarian Cancer Treatment
Elise C. Kohn, National Cancer Institute, Bethesda (MD), USA

15:50-16:10

Remarks and Conclusions
Andrés Poveda, Initia Oncology, Hospital Quirónsalud, Valencia, Spain
Valencia, 22nd February 2019

SESSION 1: TRANSLATIONAL RESEARCH
Chairs: Michael Birrer, Massachusetts General Hospital, Boston (MA), USA
Jose A. López-Guerrero, Fundación Instituto Valenciano de Oncología, Valencia, Spain

09:25-09:45 Precision medicine in epithelial ovarian cancer
Iain McNeish, Imperial College London, UK

09:45-10:05 The potential role of liquid biopsies in ovarian cancer
Martin Widschwendter, University College London, UK

10:05-10:25 TILs and PD-L1 expression in ovarian cancer: What to do with it?
George Coukos, University of Lausanne, Switzerland

SESSION 2: TREATMENT OF PRIMARY DISEASE
Chairs: Jonathan A. Ledermann, UCL Cancer Institute, University College, London, UK
Luis Chiva, Clínica Universidad de Navarra, Madrid, Spain

11:15-11:35 How to manage lymph nodes in ovarian cancer in 2019
Philipp Harter, Kliniken Essen-Mitte, Essen, Germany

11:35-11:55 Can we predict who lives long with ovarian cancer?
Michael A. Bookman, Kaiser Permanente Northern California, (CA), USA

11:55-12:15 Landscape of systemic therapy for ovarian cancer in 2019
Keiichi Fujiwara, Saitama Medical University, Saitama, Japan

SESSION 3: TREATMENT OF RECURRENT DISEASE
Chairs: Eric Pujade-Lauraine, Hôpital Hotel-Dieu, Paris, France
Ana Oaknin, Vall d’Hebron University Hospital. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain

15:00-15:20 Who needs surgery?
Jalid Sehouli, Charité University of Medicine, Berlin, Germany

15:20-15:40 Do all patients need systemic therapy?
Michael Friedlander, The Prince of Wales Hospital, Randwick, Australia

15:40-16:10 Landscape of systemic therapy for recurrent ovarian cancer in 2019
Sandro Pignata, NIRCCS National Cancer Institute “Fondazione G. Pascale”, Naples, Italy

SESSION 4: NEW DEVELOPMENTS
Chairs: Mansoor Mirza, Copenhagen University Hospital, Copenhagen, Denmark
Andrés Redondo, Hospital Universitario La Paz, Madrid, Spain

17:00-17:20 Immunotherapy in Ovarian Cancer: Still promising?
Andrea Sessa, Istituto Nazionale dei Tumori, Milan, Italy

17:20-17:40 New Strategies in Ovarian Cancer Treatment
Elke E. Reis, National Cancer Institute, Bethesda, USA

17:40-18:00 Remarks and Conclusions
Andrés Poveda, Initia Oncology, Hospital Quirónsalud, Valencia, Spain
SESSION 1: TRANSLATIONAL RESEARCH

Chairs:
Michael Birrer, Massachusetts General Hospital, Boston (MA), USA
Jose A. López-Guerrero, Fundación Instituto Valenciano de Oncología, Valencia, Spain

09:25-09:45
Precision medicine in epithelial ovarian cancer
Iain McNeish, Imperial College London, UK

09:45-10:05
The potential role of liquid biopsies in ovarian cancer
Martin Widschwendter, University College London, UK

10:05-10:25
TILs and PD-L1 expression in ovarian cancer: What to do with it?
George Coukos, University of Lausanne, Switzerland

10:25-10:45
Discussion

SESSION 2: TREATMENT OF PRIMARY DISEASE

Chairs:
Jonathan A. Ledermann, UCL Cancer Institute, University College, London, UK
Luis Chiva, Clínica Universidad de Navarra, Madrid, Spain

11:15-11:35
How to manage lymph nodes in ovarian cancer in 2019
Philipp Harter, Kliniken Essen-Mitte, Essen, Germany

11:35-11:55
Can we predict who lives long with ovarian cancer?
Michael A. Bookman, Kaiser Permanente Northern California, CA, USA

11:55-12:15
Landscape of systemic therapy for ovarian cancer in 2019
Keiichi Fujiwara, Saitama Medical University, Saitama, Japan

12:15-12:35
Discussion

SESSION 3: TREATMENT OF RECURRENT DISEASE

Chairs:
Eric Pujade-Lauraine, Hôpital Hotel-Dieu, Paris, France
Ana Oaknin, Vall d’Hebron University Hospital. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain

15:00-15:20
Who needs surgery?
Jalid Sehouli, Charité University of Medicine, Berlin, Germany

15:20-15:40
Do all patients need systemic therapy?
Michael Friedlander, The Prince of Wales Hospital, Randwick, Australia

15:40-16:10
Landscape of systemic therapy for recurrent ovarian cancer in 2019
Sandro Pignata, NIRCCS National Cancer Institute “Fondazione G. Pascale”, Naples, Italy

16:10-16:30
Discussion

SESSION 4: NEW DEVELOPMENTS

Chairs:
Mansoor Mirza, Copenhagen University Hospital, Copenhagen, Denmark
Andrés Redondo, Hospital Universitario La Paz, Madrid, Spain

17:00-17:20
Immunotherapy in Ovarian Cancer: Still promising?
Antonio González, Clínica Universidad de Navarra, Madrid, Spain

17:20-17:40
New Strategies in Ovarian Cancer Treatment
Elise C. Kohn, National Cancer Institute, Bethesda (MD), USA

17:40-18:00
Remarks and Conclusions
Andrés Poveda, Initia Oncology, Hospital Quirónsalud, Valencia, Spain
VENUE
Palau de la Música
"Iturbi" Meeting Room
Paseo de la Alameda, 30 · 46023 Valencia, Spain

SYMPOSIUM SECRETARIAT
E-mail: aocsymp2019@doctaforum.com
Phone: +34 913 72 02 03
Web: www.valencia-ovariancancersymp.org

12th International Symposium
ADVANCED
Optimal Therapy. Update
Valencia, 22nd February 2019

Director
www.valencia-ovariancancersymp.org

Andrés Poveda
Initia Oncology, Hospital Quirónsalud, Valencia, Spain

Jan B. Vermorken
Antwerp University Hospital, Edegem, Belgium

ACCREDITATION
Accreditation requested to the Spanish Authorities of Continuing Medical Education

LANGUAGE
The official language of the symposium is English. Simultaneous translation into Spanish will be provided.

SCIENTIFIC COMMITTEE
Andrés Cervantes (ESMO,GEICO)
Antonio González (ESMO,GEICO)
Andrés Poveda (ESMO,GEICO)
Jan B. Vermorken (ESMO,GEICO)

ACCREDITATION
Accreditation requested to the Spanish Authorities of Continuing Medical Education

LANGUAGE
The official language of the symposium is English. Simultaneous translation into Spanish will be provided.

Andrés Poveda
Initia Oncology, Hospital Quirónsalud, Valencia, Spain

Jan B. Vermorken
Antwerp University Hospital, Edegem, Belgium

12th International Symposium
ADVANCED
Optimal Therapy. Update
Valencia, 22nd February 2019

Director
www.valencia-ovariancancersymp.org

www.valencia-ovariancancersymp.org